Alecensa approved as first and only anaplastic lymphoma kinase inhibitor for non-small cell lung cancer
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Apr 23, 2024
0
35
